

Hepatitis B Virus Liver Failure

A Study of Ipatasertib in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy Participants

<b>Trial Status</b> Completed	<b>Trial Runs In</b> 1 Countries	<b>Trial Identifier</b> NCT03341884 GP40200
----------------------------------	-------------------------------------	--

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

*Trial Summary:*

This is a Phase 1 study evaluating the pharmacokinetics, tolerability and safety of a single dose of ipatasertib in participants with mild, moderate or severe hepatic impairment compared to healthy participants.

<b>Genentech, Inc.</b> Sponsor	<b>Phase 1</b> Phase
<b>NCT03341884 GP40200</b> Trial Identifiers	

*Eligibility Criteria:*

<b>Gender</b> All	<b>Age</b> >= 18 Years & <= 74 Years	<b>Healthy Volunteers</b> Accepts Healthy Volunteers
----------------------	---	---